Helius Medical Technologies Inc (TSE:HSM) – Stock analysts at Oppenheimer reduced their Q2 2019 earnings per share estimates for shares of Helius Medical Technologies in a report issued on Monday, May 13th. Oppenheimer analyst S. Lichtman now anticipates that the company will post earnings per share of ($0.34) for the quarter, down from their prior estimate of ($0.31). Oppenheimer also issued estimates for Helius Medical Technologies’ Q3 2019 earnings at ($0.36) EPS, Q4 2019 earnings at ($0.40) EPS, FY2019 earnings at ($1.02) EPS, FY2020 earnings at ($1.52) EPS and FY2021 earnings at ($1.36) EPS.
Helius Medical Technologies stock opened at C$2.95 on Thursday. The firm has a market cap of $70.87 million and a PE ratio of -2.50. The company has a current ratio of 2.11, a quick ratio of 2.00 and a debt-to-equity ratio of 6.20. Helius Medical Technologies has a 1-year low of C$2.35 and a 1-year high of C$17.20.
Helius Medical Technologies (TSE:HSM) last released its quarterly earnings results on Thursday, March 14th. The company reported C($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.27) by C($0.02). The firm had revenue of C$0.63 million for the quarter.
Helius Medical Technologies Company Profile
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, or acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a medical device in Canada for the treatment of chronic balance deficit associated with a mild to moderate traumatic brain injury.
Featured Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.